{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:13:01Z","timestamp":1782889981939,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172052"],"award-info":[{"award-number":["82172052"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Natural Science Foundation","award":["Z210007"],"award-info":[{"award-number":["Z210007"]}]},{"name":"National High-Level Hospital Clinical Research Funding","award":["2022CR34"],"award-info":[{"award-number":["2022CR34"]}]},{"name":"Youth Clinical Research Special Fund Project of Peking University First Hospital","award":["2023YC26"],"award-info":[{"award-number":["2023YC26"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s00259-025-07220-3","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T01:42:22Z","timestamp":1746668542000},"page":"4525-4538","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["HER2-targeted PET\/CT imaging provides potential biomarkers for differentiating HER2-zero, -low, and -positive breast cancer"],"prefix":"10.1007","volume":"52","author":[{"given":"Yuan","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojiang","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijian","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinzhi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9236-3014","authenticated-orcid":false,"given":"Ling","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5740-0602","authenticated-orcid":false,"given":"Jingming","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6960-3163","authenticated-orcid":false,"given":"Meng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"key":"7220_CR1","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/s0140-6736(22)02420-5","volume":"401","author":"SA Hurvitz","year":"2023","unstructured":"Hurvitz SA, Hegg R, Chung WP, Im SA, Jacot W, Ganju V, et al. Trastuzumab Deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023;401:105\u201317. https:\/\/doi.org\/10.1016\/s0140-6736(22)02420-5.","journal-title":"Lancet"},{"key":"7220_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab Deruxtecan in previously treated HER2-Low advanced breast cancer. N Engl J Med. 2022;387:9\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203690.","journal-title":"N Engl J Med"},{"key":"7220_CR3","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","volume":"30","author":"J Cort\u00e9s","year":"2024","unstructured":"Cort\u00e9s J, Hurvitz SA, Im SA, Iwata H, Curigliano G, Kim SB, et al. Trastuzumab Deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nat Med. 2024;30:2208\u201315. https:\/\/doi.org\/10.1038\/s41591-024-03021-7.","journal-title":"Nat Med"},{"key":"7220_CR4","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.trecan.2023.11.001","volume":"10","author":"C Valenza","year":"2024","unstructured":"Valenza C, Guidi L, Battaiotto E, Trapani D, Sartore Bianchi A, Siena S, et al. Targeting HER2 heterogeneity in breast and Gastrointestinal cancers. Trends Cancer. 2024;10:113\u201323. https:\/\/doi.org\/10.1016\/j.trecan.2023.11.001.","journal-title":"Trends Cancer"},{"key":"7220_CR5","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s13058-024-01921-7","volume":"26","author":"H Chen","year":"2024","unstructured":"Chen H, Liu Y, Zhao J, Jia X, Chai F, Peng Y, et al. Quantification of intratumoral heterogeneity using habitat-based MRI radiomics to identify HER2-positive, -low and -zero breast cancers: a multicenter study. Breast Cancer Res. 2024;26:160. https:\/\/doi.org\/10.1186\/s13058-024-01921-7.","journal-title":"Breast Cancer Res"},{"key":"7220_CR6","doi-asserted-by":"publisher","first-page":"e222646","DOI":"10.1148\/radiol.222646","volume":"308","author":"T Ramtohul","year":"2023","unstructured":"Ramtohul T, Djerroudi L, Lissavalid E, Nhy C, Redon L, Ikni L, et al. Multiparametric MRI and radiomics for the prediction of HER2-Zero, -Low, and -Positive breast cancers. Radiology. 2023;308:e222646. https:\/\/doi.org\/10.1148\/radiol.222646.","journal-title":"Radiology"},{"key":"7220_CR7","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1002\/jmri.28628","volume":"58","author":"X Bian","year":"2023","unstructured":"Bian X, Du S, Yue Z, Gao S, Zhao R, Huang G, et al. Potential antihuman epidermal growth factor receptor 2 target therapy beneficiaries: the role of MRI-Based radiomics in distinguishing human epidermal growth factor receptor 2-Low status of breast cancer. J Magn Reson Imaging. 2023;58:1603\u201314. https:\/\/doi.org\/10.1002\/jmri.28628.","journal-title":"J Magn Reson Imaging"},{"issue":"Suppl 1","key":"7220_CR8","doi-asserted-by":"publisher","first-page":"s17","DOI":"10.2967\/jnumed.115.157859","volume":"57","author":"D Groheux","year":"2016","unstructured":"Groheux D, Cochet A, Humbert O, Alberini JL, Hindi\u00e9 E, Mankoff D. \u00b9\u2078F-FDG PET\/CT for staging and restaging of breast cancer. J Nucl Med. 2016;57(Suppl 1):s17\u201326. https:\/\/doi.org\/10.2967\/jnumed.115.157859.","journal-title":"J Nucl Med"},{"key":"7220_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae185","author":"Y Wu","year":"2024","unstructured":"Wu Y, Li Y, Chen B, Zhang Y, Xing W, Guo B, et al. 18F-FDG PET\/CT for early prediction of pathological complete response in breast cancer neoadjuvant therapy: a retrospective analysis. Oncologist. 2024. https:\/\/doi.org\/10.1093\/oncolo\/oyae185.","journal-title":"Oncologist"},{"key":"7220_CR10","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s40644-024-00812-6","volume":"24","author":"Y Gao","year":"2024","unstructured":"Gao Y, Yin L, Ma L, Wu C, Zhu X, Liu H, et al. Comparative analysis of metabolic characteristics and prognostic stratification of HER2-low and HER2-zero breast cancer using 18F-FDG PET\/CT imaging. Cancer Imaging. 2024;24:166. https:\/\/doi.org\/10.1186\/s40644-024-00812-6.","journal-title":"Cancer Imaging"},{"key":"7220_CR11","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1053\/j.semnuclmed.2022.05.001","volume":"52","author":"D Groheux","year":"2022","unstructured":"Groheux D. FDG-PET\/CT for primary staging and detection of recurrence of breast cancer. Semin Nucl Med. 2022;52:508\u201319. https:\/\/doi.org\/10.1053\/j.semnuclmed.2022.05.001.","journal-title":"Semin Nucl Med"},{"key":"7220_CR12","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.2967\/jnumed.124.267636","volume":"65","author":"B Eisses","year":"2024","unstructured":"Eisses B, van Geel JJL, Brouwers AH, Bensch F, Elias SG, Kuip EJM, et al. Whole-Body HER2 heterogeneity identified on HER2 PET in HER2-Negative, -Low, and -Positive metastatic breast cancer. J Nucl Med. 2024;65:1540\u20137. https:\/\/doi.org\/10.2967\/jnumed.124.267636.","journal-title":"J Nucl Med"},{"key":"7220_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/rlu.0000000000005535","volume":"50","author":"X Jin","year":"2025","unstructured":"Jin X, Zhang Y, Cao X, Wang P, Ren C, Cai J, et al. HER2-Targeted affibody molecule 99mTc-ABH2 for imaging HER2 expression in breast cancer. Clin Nucl Med. 2025;50:25\u201330. https:\/\/doi.org\/10.1097\/rlu.0000000000005535.","journal-title":"Clin Nucl Med"},{"key":"7220_CR14","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2967\/jnumed.108.057919","volume":"50","author":"A Orlova","year":"2009","unstructured":"Orlova A, W\u00e5llberg H, Stone-Elander S, Tolmachev V. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model. J Nucl Med. 2009;50:417\u201325. https:\/\/doi.org\/10.2967\/jnumed.108.057919.","journal-title":"J Nucl Med"},{"key":"7220_CR15","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00259-020-04898-5","volume":"48","author":"N Zhou","year":"2021","unstructured":"Zhou N, Liu C, Guo X, Xu Y, Gong J, Qi C, et al. Impact of (68)Ga-NOTA-MAL-MZHER2 PET imaging in advanced gastric cancer patients and therapeutic response monitoring. Eur J Nucl Med Mol Imaging. 2021;48:161\u201375. https:\/\/doi.org\/10.1007\/s00259-020-04898-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7220_CR16","doi-asserted-by":"publisher","first-page":"10990","DOI":"10.1039\/c8ra10271f","volume":"9","author":"Y Pan","year":"2019","unstructured":"Pan Y, Yang Z, Xu Y, Bai Z, Pan D, Yang R, et al. Targeting HER2-positive gastric cancer with a novel (18)F-labeled Z(HER2:342) probe. RSC Adv. 2019;9:10990\u20138. https:\/\/doi.org\/10.1039\/c8ra10271f.","journal-title":"RSC Adv"},{"key":"7220_CR17","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1365-2559.1991.tb00229.x","volume":"19","author":"CW Elston","year":"1991","unstructured":"Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403\u201310. https:\/\/doi.org\/10.1111\/j.1365-2559.1991.tb00229.x.","journal-title":"Histopathology"},{"key":"7220_CR18","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1200\/jco.2009.25.6529","volume":"28","author":"ME Hammond","year":"2010","unstructured":"Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American society of clinical oncology\/college of American pathologists guideline recommendations for immunohistochemical testing of Estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784\u201395. https:\/\/doi.org\/10.1200\/jco.2009.25.6529.","journal-title":"J Clin Oncol"},{"key":"7220_CR19","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/jco.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of American pathologists clinical practice guideline focused update. J Clin Oncol. 2018;36:2105\u201322. https:\/\/doi.org\/10.1200\/jco.2018.77.8738.","journal-title":"J Clin Oncol"},{"key":"7220_CR20","doi-asserted-by":"publisher","first-page":"e232209","DOI":"10.1148\/radiol.232209","volume":"311","author":"X Guo","year":"2024","unstructured":"Guo X, Zhou N, Liu J, Ding J, Liu T, Song G, et al. Comparison of an Affibody-based molecular probe and (18)F-FDG for detecting HER2-Positive breast cancer at PET\/CT. Radiology. 2024;311:e232209. https:\/\/doi.org\/10.1148\/radiol.232209.","journal-title":"Radiology"},{"key":"7220_CR21","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","volume":"391","author":"A Bardia","year":"2024","unstructured":"Bardia A, Hu X, Dent R, Yonemori K, Barrios CH, O\u2019Shaughnessy JA, et al. Trastuzumab Deruxtecan after endocrine therapy in metastatic breast cancer. N Engl J Med. 2024;391:2110\u201322. https:\/\/doi.org\/10.1056\/NEJMoa2407086.","journal-title":"N Engl J Med"},{"key":"7220_CR22","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/s00259-020-04996-4","volume":"48","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Wu C, Li W, Chen X, Li Z, Liao X, et al. 2-[(18)F]FDG PET\/CT parameters associated with WHO\/ISUP grade in clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2021;48:570\u20139. https:\/\/doi.org\/10.1007\/s00259-020-04996-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7220_CR23","doi-asserted-by":"publisher","unstructured":"Chardin D, Paquet M, Schiappa R, Darcourt J, Bailleux C, Poudenx M, et al. Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study. J Immunother Cancer. 2020;8. https:\/\/doi.org\/10.1136\/jitc-2020-000645.","DOI":"10.1136\/jitc-2020-000645"},{"key":"7220_CR24","doi-asserted-by":"publisher","first-page":"1049043","DOI":"10.3389\/fimmu.2022.1049043","volume":"13","author":"Y Gao","year":"2022","unstructured":"Gao Y, Wu C, Chen X, Ma L, Zhang X, Chen J, et al. PET\/CT molecular imaging in the era of immune-checkpoint inhibitors therapy. Front Immunol. 2022;13:1049043. https:\/\/doi.org\/10.3389\/fimmu.2022.1049043.","journal-title":"Front Immunol"},{"key":"7220_CR25","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1053\/j.semnuclmed.2007.01.003","volume":"37","author":"RG Abramson","year":"2007","unstructured":"Abramson RG, Mavi A, Cermik T, Basu S, Wehrli NE, Houseni M, et al. Age-related structural and functional changes in the breast: multimodality correlation with digital mammography, computed tomography, magnetic resonance imaging, and positron emission tomography. Semin Nucl Med. 2007;37:146\u201353. https:\/\/doi.org\/10.1053\/j.semnuclmed.2007.01.003.","journal-title":"Semin Nucl Med"},{"issue":"Suppl 3","key":"7220_CR26","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1016\/s0305-7372(10)70022-0","volume":"36","author":"V Guarneri","year":"2010","unstructured":"Guarneri V, Barbieri E, Dieci MV, Piacentini F, Conte P. Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. Cancer Treat Rev. 2010;36(Suppl 3):S62\u20136. https:\/\/doi.org\/10.1016\/s0305-7372(10)70022-0.","journal-title":"Cancer Treat Rev"},{"key":"7220_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaoncol.2021.7239","volume":"8","author":"AI Fernandez","year":"2022","unstructured":"Fernandez AI, Liu M, Bellizzi A, Brock J, Fadare O, Hanley K, et al. Examination of low ERBB2 protein expression in breast cancer tissue. JAMA Oncol. 2022;8:1\u20134. https:\/\/doi.org\/10.1001\/jamaoncol.2021.7239.","journal-title":"JAMA Oncol"},{"key":"7220_CR28","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/s41374-022-00804-9","volume":"102","author":"M Moutafi","year":"2022","unstructured":"Moutafi M, Robbins CJ, Yaghoobi V, Fernandez AI, Martinez-Morilla S, Xirou V, et al. Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer. Lab Invest. 2022;102:1101\u20138. https:\/\/doi.org\/10.1038\/s41374-022-00804-9.","journal-title":"Lab Invest"},{"key":"7220_CR29","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1200\/jco.19.02488","volume":"38","author":"P Tarantino","year":"2020","unstructured":"Tarantino P, Hamilton E, Tolaney SM, Cortes J, Morganti S, Ferraro E, et al. HER2-Low breast cancer: pathological and clinical landscape. J Clin Oncol. 2020;38:1951\u201362. https:\/\/doi.org\/10.1200\/jco.19.02488.","journal-title":"J Clin Oncol"},{"key":"7220_CR30","doi-asserted-by":"publisher","first-page":"110368","DOI":"10.1016\/j.radonc.2024.110368","volume":"197","author":"B Ma","year":"2024","unstructured":"Ma B, Guo J, De Biase A, van Dijk LV, van Ooijen PMA, Langendijk JA, et al. PET\/CT based transformer model for multi-outcome prediction in oropharyngeal cancer. Radiother Oncol. 2024;197:110368. https:\/\/doi.org\/10.1016\/j.radonc.2024.110368.","journal-title":"Radiother Oncol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07220-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07220-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07220-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T08:36:31Z","timestamp":1759394191000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07220-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["7220"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07220-3","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]},"assertion":[{"value":"15 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This single-center prospective clinical trial was performed at Peking University First Hospital, and the study was approved by the institutional ethics committee (2023SR550-002) and registered at ClinicalTrials.gov (NCT06289517).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients provided written informed consent prior to imaging.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}